Orion Bemoans Bad Luck In Winner-Takes-All Biosimilar Tenders
Management Also Discusses European Generics After Shelving Spiriva Rival
Finland’s Orion is continuing to await the potentially uplifting effect of its biosimilar partnership with Aurobindo’s CuraTeQ Biologics, after another tricky year.
You may also be interested in...
Orion Bags Another Big Pharma Partner With Merck & Co Prostate Cancer Deal
The Finnish group has concluded an extensive search to partner its first-in-class CYP11A1 inhibitor, banking an impressive $290m upfront fee for the Phase II drug which is being evaluated for metastatic castration-resistant prostate cancer.
Aurobindo’s CuraTeQ Expands Biosimilars Deal With Orion For Baltic Countries
Aurobindo’s CuraTeQ Biologics has expanded its biosimilar distribution agreement with Finnish Player Orion. After covering the Nordics, Austria, Hungary and Slovenia, the partnering companies have decided to expand to the Baltic countries, with launches slated for between 2023 and 2026.
Orion Defends Position In Declining Finnish Market
Amid declining sales of drugs covered by reference prices in Finland, local leader Orion says it has been able to slightly strengthen its market position.